Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit
Kaleido Biosciences (Nasdaq: KLDO) announced that CEO Dan Menichella will participate in an analyst-led fireside chat at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kaleido Biosciences (Nasdaq: KLDO) announced that CEO Dan Menichella will participate in an analyst-led fireside chat at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The event emphasizes Kaleido's innovative, chemistry-driven approach to targeting the microbiome to treat diseases. The webcast will be available at 8 am EDT on Kaleido’s website, with an archived replay accessible for 90 days post-event. Kaleido focuses on developing Microbiome Metabolic Therapies (MMT) aimed at enhancing gut health and addressing unmet medical needs.
Details
News Market Reaction – KLDO
The recorded move for KLDO in the trading session of this news was +9.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit.
The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 90 days following the event.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com
Investors
Mike Biega
Solebury Trout
617-221-9660
mbiega@soleburytrout.com
Media
Amy Bonanno
Solebury Trout
914-450-0349
abonanno@soleburytrout.com
SOURCE: Kaleido Biosciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.